Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Abstract Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent
azacytidine, achieves complete remission with or without count recovery in∼ 70% of …

Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …

Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous hematological
malignancy. Although immunotherapy may be an attractive modality to exploit in patients …

Background Immune exhaustion and senescence are dominant dysfunctional states of
effector T cells and major hurdles for the success of cancer immunotherapy. In the current …

Sustained expression of programmed cell death receptor-1 (PD-1) is correlated with the
exhaustion of T cells, and blockade of the PD-1 pathway is an effective immunotherapeutic …

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly
because of the lack of actionable immune targets. Using an original proteogenomic …

Understanding factors that shape the immune landscape across hematological
malignancies is essential for immunotherapy development. We integrated over 8,000 …